AIM:MXCT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally.


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has MaxCyte's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MXCT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.7%

MXCT

-1.8%

GB Biotechs

1.3%

GB Market


1 Year Return

36.5%

MXCT

11.5%

GB Biotechs

-15.0%

GB Market

Return vs Industry: MXCT exceeded the UK Biotechs industry which returned 10.8% over the past year.

Return vs Market: MXCT exceeded the UK Market which returned -16.2% over the past year.


Shareholder returns

MXCTIndustryMarket
7 Day6.7%-1.8%1.3%
30 Day14.3%-3.4%-0.3%
90 Day53.8%24.3%18.1%
1 Year36.5%36.5%12.4%11.5%-11.0%-15.0%
3 Year-14.9%-14.9%8.9%7.2%-2.2%-14.2%
5 Yearn/a49.8%46.1%18.2%-8.1%

Price Volatility Vs. Market

How volatile is MaxCyte's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MaxCyte undervalued compared to its fair value and its price relative to the market?

10.52x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MXCT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MXCT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MXCT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MXCT is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MXCT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MXCT is overvalued based on its PB Ratio (10.5x) compared to the GB Biotechs industry average (3.5x).


Next Steps

Future Growth

How is MaxCyte forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

67.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MXCT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: MXCT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MXCT's is expected to become profitable in the next 3 years.

Revenue vs Market: MXCT's revenue (13.6% per year) is forecast to grow faster than the UK market (3.2% per year).

High Growth Revenue: MXCT's revenue (13.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MXCT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MaxCyte performed over the past 5 years?

-31.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MXCT is currently unprofitable.

Growing Profit Margin: MXCT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MXCT is unprofitable, and losses have increased over the past 5 years at a rate of -31.3% per year.

Accelerating Growth: Unable to compare MXCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MXCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: MXCT has a negative Return on Equity (-94.8%), as it is currently unprofitable.


Next Steps

Financial Health

How is MaxCyte's financial position?


Financial Position Analysis

Short Term Liabilities: MXCT's short term assets ($24.5M) exceed its short term liabilities ($9.3M).

Long Term Liabilities: MXCT's short term assets ($24.5M) exceed its long term liabilities ($7.0M).


Debt to Equity History and Analysis

Debt Level: MXCT's debt to equity ratio (36%) is considered satisfactory.

Reducing Debt: MXCT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MXCT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MXCT has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 42.5% each year.


Next Steps

Dividend

What is MaxCyte current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MXCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MXCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MXCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MXCT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MXCT's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Doug Doerfler (64yo)

21.08yrs

Tenure

US$705,250

Compensation

Mr. Douglas Arthur Doerfler, also known as Doug, Co-founded MaxCyte, Inc. in June 1999 and has been its Chief Executive Officer and President since June 1999. Mr. Doerfler served senior corporate developme ...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD705.25K) is about average for companies of similar size in the UK market ($USD684.29K).

Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Doerfler
Co-Founder21.08yrsUS$705.25k0.57% $866.4k
Ronald Holtz
CFO, Company Secretary & Director4.25yrsUS$445.93k0.20% $300.5k
Maher Masoud
Executive VP & General Counsel2.83yrsno datano data
Thomas Ross
Executive Vice President of Global Sales6.5yrsno datano data
Markus Hunkeler
Vice President of Marketing4.5yrsno datano data
Brad Calvin
Executive Vice President of Global Commercial Operations2.92yrsno datano data
Claudio Dansky Ullmann
Chief Medical Officer2.25yrsno datano data
Shruti Abbato
Executive Vice President of Business Development for CARMA Cellular Therapies0.58yrno datano data

3.7yrs

Average Tenure

62yo

Average Age

Experienced Management: MXCT's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Douglas Doerfler
Co-Founder21.08yrsUS$705.25k0.57% $866.4k
Ronald Holtz
CFO, Company Secretary & Director4.25yrsUS$445.93k0.20% $300.5k
William Brooke
Independent Non-Executive Directorno dataUS$51.00k0.066% $100.6k
Arthur Mandell
Independent Non-Executive Director14.17yrsUS$45.50k0.49% $749.0k
J. Thompson
Independent Non-Executive Chairmanno dataUS$68.00k0.14% $221.8k
Richard Douglas
Independent Non-Executive Director2.42yrsUS$35.00kno data
Stanley Erck
Independent Non-Executive Director15.25yrsUS$40.00k0.32% $495.5k
John Johnston
Independent Non-Executive Directorno dataUS$40.50k0.16% $241.2k

14.2yrs

Average Tenure

65.5yo

Average Age

Experienced Board: MXCT's board of directors are seasoned and experienced ( 14.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.6%.


Top Shareholders

Company Information

MaxCyte, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MaxCyte, Inc.
  • Ticker: MXCT
  • Exchange: AIM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£153.170m
  • Shares outstanding: 76.59m
  • Website: https://www.maxcyte.com

Number of Employees


Location

  • MaxCyte, Inc.
  • 22 Firstfield Road
  • Suite 110
  • Gaithersburg
  • Maryland
  • 20878
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MXCTAIM (London Stock Exchange AIM Market)YesCommon StockGBGBPMar 2016
MAXCOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2016
MXCLAIM (London Stock Exchange AIM Market)ORD USD0.01 (DI) REG SGBGBPMay 2020

Biography

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/02 21:06
End of Day Share Price2020/07/02 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.